Type 2 diabetes drug aids weight loss, study finds
Patients given GLP-1 receptor agonists to treat obesity lost weight compared with those treated with placebo.
Source: Dr P Marazzi / Science Photo Library
Up to 80% of those treated with GLP-1 receptor agonists lose weight, according to a randomised, placebo-controlled study in 957 individuals without diabetes.
Researchers evaluated the use of semaglutide (SEMA) for the treatment of obesity in a dose-ranging study (doses: 0.05mg, 0.1mg, 0.2mg, 0.3mg or 0.4mg) versus placebo and an active liraglutide (LIRA) control, each combined with counselling.
After one year, estimated mean weight loss was –2.3% in the placebo group and –7.8% in the LIRA group. In the SEMA treatment group, weight loss ranged from –6% at 0.05mg to –13.8% at 0.4mg.
An estimated 23% of participants lost weight in the placebo group compared with 66% in the LIRA group. In the SEMA group, it ranged from 54% of subjects in the 0.05mg group to 83% in the 0.4mg group.
Presenting their findings at the Endocrine Society’s 100th annual meeting in Chicago (18 March 2018), the researchers concluded that, combined with counselling, SEMA was well tolerated and led to higher weight loss than placebo in obese people without diabetes.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205053
Recommended from Pharmaceutical Press
An innovative book which presents statistics in the context of clinical trials conducted during pharmaceutical drug development.£38.00Buy now